New Demand & Necessity Buoy Industry -- Insight on MultiCell Technologies, Inc. and Aradigm Corporation

BEIJING--(Marketwire - 06/02/11) - Today, www.GlobalEquityReporter.com announced its research report highlighting MultiCell Technologies, Inc. (OTC.BB:MCET - News) and Aradigm Corporation (OTC.BB:ARDM - News). Full report download is available at www.GlobalEquityReporter.com/access.php.Several new innovators within the healthcare field have buoyed an influx of new interest to the industry. Combining medical technology with human touch, the healthcare industry diagnoses, treats, and administers care around the clock- responding to the needs of millions of people. Occupational projections show concentrated growth within the industry, a result of the growing demand for improved medical care in both developed and developing economies. The global medical industry is one of the world's fastest growing, absorbing over 10% of the Gross Domestic Product of most developed countries.
Global Equity is reporting on MultiCell Technologies, Inc. for its engagement in developing therapeutics and discovery tools to address unmet medical needs for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology and peripheral vessel applications. MultiCell is pursuing research and development targeting degenerative neurological diseases, including multiple sclerosis (MS) and cancer. The full report and profile on MultiCell Technologies, Inc. (OTC.BB:MCET - News) is available here: www.GlobalEquityReporter.com/get.PDF.1824.php.Global Equity Reporter brings Aradigm Corporation to light as a breath of fresh air, as a specialty pharmaceutical company focused on advanced inhalation delivery. The company's emphasis is directly on the antibiotic ciprofloxacin, which is currently FDA approved. Aradigm has discovered that delivery by inhalation can effectively treat infections associated with severe respiratory diseases such as: cystic fibrosis and bronchiectasis. The full report and profile on Aradigm Corporation (OTC.BB:ARDM - News) is available here: www.GlobalEquityReporter.com/get.PDF.1937.php.About Global Equity Reporter
Global Equity Reporter is a premier source for microcap research - providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers. We report potential market opportunity to our members before the same situation grows to become strong market momentum, enabling our members to see strong market growth by delivering information before the crowd.